Atlas Trials

RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.

Clinical trial NCT05758831 · RECRUITING

Trial details

NCT number
NCT05758831
Sponsor
Rennes University Hospital
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Multiple SclerosisRelapsing-remitting Multiple Sclerosis
Start date
2023-06-01
Primary completion
2030-03-31
Enrollment
386

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.